{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T14:02:15Z","timestamp":1648908135146},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T00:00:00Z","timestamp":1380240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s00059-013-3942-8","type":"journal-article","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T12:00:45Z","timestamp":1380110445000},"page":"993-1000","source":"Crossref","is-referenced-by-count":2,"title":["Thrombin activatable fibrinolysis inhibitor"],"prefix":"10.1007","volume":"39","author":[{"given":"M.N.","family":"Yildirim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Selcoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Uysal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.B.","family":"Nacar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Demircelik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.I.","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Eryonucu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,27]]},"reference":[{"key":"3942_CR1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0002-8703(72)90307-9","volume":"84","author":"Tambe","year":"1972","unstructured":"Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E (1972) Angina pectoris and slow flow velocity of dye in coronary arteries\u2014a new angiographic finding. Am Heart J 84(1):66\u201371","journal-title":"Am Heart J"},{"key":"3942_CR2","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0735-1097(99)00335-6","volume":"34","author":"Gibson","year":"1999","unstructured":"Gibson CM, Ryan KA, Murphy SA et al (1999) Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction. J Am Coll Cardiol 34(4):974\u2013982","journal-title":"J Am Coll Cardiol"},{"key":"3942_CR3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/(SICI)1097-0304(199604)37:4<375::AID-CCD7>3.0.CO;2-8","volume":"37","author":"Mangieri","year":"1996","unstructured":"Mangieri E, Macchiarelli G, Ciavolella M et al (1996) Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn 37(4):375\u2013381","journal-title":"Cathet Cardiovasc Diagn"},{"key":"3942_CR4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/0002-9149(94)90739-0","volume":"74","author":"Diver","year":"1994","unstructured":"Diver DJ, Bier JD, Ferreira PE et al (1994) Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial). Am J Cardiol 74(6):531\u2013537","journal-title":"Am J Cardiol"},{"key":"3942_CR5","first-page":"605","volume":"29","author":"Cesar","year":"1996","unstructured":"Cesar LA, Ramires JA, Serrano Junior CV et al (1996) Slow coronary run-off in patients with angina pectoris: clinical significance and thallium-201 scintigraphic study. Braz J Med Biol Res 29(5):605\u2013613","journal-title":"Braz J Med Biol Res"},{"key":"3942_CR6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0002-8703(03)00124-8","volume":"146","author":"Beltrame","year":"2003","unstructured":"Beltrame JF, Limaye SB, Wuttke RD, Horowitz JD (2003) Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon. Am Heart J 146(1):84\u201390","journal-title":"Am Heart J"},{"key":"3942_CR7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00004424-197703000-00003","volume":"12","author":"Levin","year":"1977","unstructured":"Levin DC, Phillips DA, Lee-Son S, Maroko PR (1977) Hemodynamic changes distal to selective arterial injections. Invest Radiol 12(2):116\u2013120","journal-title":"Invest Radiol"},{"key":"3942_CR8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/clc.4950260705","volume":"26","author":"Kelly","year":"2003","unstructured":"Kelly RF, Sompalli V, Sattar P, Khankari K (2003) Increased TIMI frame counts in cocaine users: a case for increased microvascular resistance in the absence of epicardial coronary disease or spasm. Clin Cardiol 26(7):319\u2013322","journal-title":"Clin Cardiol"},{"key":"3942_CR9","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.mehy.2005.09.028","volume":"66","author":"Li","year":"2006","unstructured":"Li JJ, Xu B, Li ZC et al (2006) Is slow coronary flow associated with inflammation? Med Hypotheses 66(3):504\u2013508","journal-title":"Med Hypotheses"},{"key":"3942_CR10","first-page":"222","volume":"3","author":"Yazici","year":"2003","unstructured":"Yazici M, Demircan S, Aksakal E et al (2003) Plasma insulin, glucose and lipid levels, and their relations with corrected TIMI frame count in patients with slow coronary flow. Anadolu Kardiyol Derg 3(3):222\u2013226","journal-title":"Anadolu Kardiyol Derg"},{"key":"3942_CR11","doi-asserted-by":"crossref","first-page":"21833","DOI":"10.1016\/S0021-9258(18)54713-X","volume":"266","author":"Eaton","year":"1991","unstructured":"Eaton DL, Malloy BE, Tsai SP et al (1991) Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 266(32):21833\u201321838","journal-title":"J Biol Chem"},{"key":"3942_CR12","first-page":"236","volume":"4","author":"Cusman","year":"1999","unstructured":"Cusman M (1999) Hemostatic risk factor for cardiovascular disease. Heamatology 4:236\u2013242","journal-title":"Heamatology"},{"key":"3942_CR13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1055\/s-0037-1615366","volume":"80","author":"Mosnier","year":"1998","unstructured":"Mosnier LO, Borne PA von dem, Meijers JC, Bouma BN (1998) Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 80(5):829\u2013835","journal-title":"Thromb Haemost"},{"key":"3942_CR14","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1055\/s-0037-1613941","volume":"83","author":"Chetaille","year":"2000","unstructured":"Chetaille P, Alessi MC, Kouassi D et al (2000) Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 83(6):902\u2013905","journal-title":"Thromb Haemost"},{"key":"3942_CR15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/clinchem\/45.6.807","volume":"45","author":"Schatteman","year":"1999","unstructured":"Schatteman KA, Goossens FJ, Scharpe SS et al (1999) Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma. Clin Chem 45(6 Pt 1):807\u2013813","journal-title":"Clin Chem"},{"key":"3942_CR16","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1055\/s-0037-1614029","volume":"84","author":"Silveira","year":"2000","unstructured":"Silveira A, Schatteman K, Goossens F et al (2000) Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 84(3):364\u2013368","journal-title":"Thromb Haemost"},{"key":"3942_CR17","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.CIR.93.5.879","volume":"93","author":"Gibson","year":"1996","unstructured":"Gibson CM, Cannon CP, Daley WL et al (1996) TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93(5):879\u2013888","journal-title":"Circulation"},{"key":"3942_CR18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2143\/AC.59.2.2005166","volume":"59","author":"Pekdemir","year":"2004","unstructured":"Pekdemir H, Cin VG, Cicek D et al (2004) Slow coronary flow may be a sign of diffuse atherosclerosis. Contribution of FFR and IVUS. Acta Cardiol 59(2):127\u2013133","journal-title":"Acta Cardiol"},{"key":"3942_CR19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jelectrocard.2006.06.004","volume":"41","author":"Dogan","year":"2008","unstructured":"Dogan SM, Yildirim N, Gursurer M et al (2008) P-wave duration and dispersion in patients with coronary slow flow and its relationship with Thrombolysis in Myocardial Infarction frame count. J Electrocardiol 41(1):55\u201359","journal-title":"J Electrocardiol"},{"key":"3942_CR20","first-page":"19","volume":"7","author":"Avsar","year":"2007","unstructured":"Avsar O, Demir I, Ekiz O et al (2007) Relationship between the slow coronary flow and carotid artery intima-media thickness. Anadolu Kardiyol Derg 7(1):19\u201323","journal-title":"Anadolu Kardiyol Derg"},{"key":"3942_CR21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clinbiochem.2006.10.020","volume":"40","author":"Boffa","year":"2007","unstructured":"Boffa MB, Koschinsky ML (2007) Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 40(7):431\u2013442","journal-title":"Clin Biochem"},{"key":"3942_CR22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1538-7836.2008.03221.x","volume":"7","author":"Tregouet","year":"2009","unstructured":"Tregouet DA, Schnabel R, Alessi MC et al (2009) Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 7:49\u201357","journal-title":"J Thromb Haemost"},{"key":"3942_CR23","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1161\/01.CIR.93.7.1328","volume":"93","author":"Redlitz","year":"1996","unstructured":"Redlitz A, Nicolini FA, Malycky JL et al (1996) Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation 93(7):1328\u20131330","journal-title":"Circulation"},{"key":"3942_CR24","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1538-7836.2004.00605.x","volume":"2","author":"Leurs","year":"2004","unstructured":"Leurs J, Nerme V, Sim Y, Hendriks D (2004) Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism. J Thromb Haemost 2(3):416\u2013423","journal-title":"J Thromb Haemost"},{"key":"3942_CR25","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1055\/s-0037-1613349","volume":"88","author":"Schroeder","year":"2002","unstructured":"Schroeder V, Chatterjee T, Mehta H et al (2002) Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 88(6):1020\u20131025","journal-title":"Thromb Haemost"},{"key":"3942_CR26","first-page":"166","volume":"50","author":"Lisowski","year":"2005","unstructured":"Lisowski P, Malyszko J, Hirnle T et al (2005) Thrombin activatable fibrinolysis inhibitor (TAFI) in stable angina pectoris patients undergoing coronary artery bypass grafting (CABG). Rocz Akad Med Bialymst 50:166\u2013172","journal-title":"Rocz Akad Med Bialymst"},{"key":"3942_CR27","first-page":"880","volume":"89","author":"Santamaria","year":"2004","unstructured":"Santamaria A, Martinez-Rubio A, Borrell M et al (2004) Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica 89(7):880\u2013881","journal-title":"Haematologica"},{"key":"3942_CR28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.thromres.2005.10.006","volume":"118","author":"Paola","year":"2006","unstructured":"Paola Cellai A, Antonucci E, Alessandrello Liotta A et al (2006) TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit. Thromb Res 118(4):495\u2013500","journal-title":"Thromb Res"},{"key":"3942_CR29","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1182\/blood-2003-10-3422","volume":"103","author":"Eichinger","year":"2004","unstructured":"Eichinger S, Schonauer V, Weltermann A et al (2004) Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 103(10):3773\u20133776","journal-title":"Blood"},{"key":"3942_CR30","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1161\/01.ATV.20.9.2156","volume":"20","author":"Juhan-Vague","year":"2000","unstructured":"Juhan-Vague I, Renucci JF, Grimaux M et al (2000) Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 20(9):2156\u20132161","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3942_CR31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/hrt.59.5.535","volume":"59","author":"Aznar","year":"1988","unstructured":"Aznar J, Estelles A, Tormo G et al (1988) Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 59(5):535\u2013541","journal-title":"Br Heart J"},{"key":"3942_CR32","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1161\/01.CIR.98.21.2241","volume":"98","author":"Thogersen","year":"1998","unstructured":"Thogersen AM, Jansson JH, Boman K et al (1998) High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98(21):2241\u20132247","journal-title":"Circulation"},{"key":"3942_CR33","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1160\/TH06-02-0094","volume":"97","author":"Sosothikul","year":"2007","unstructured":"Sosothikul D, Seksarn P, Pongsewalak S et al (2007) Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection. Thromb Haemost 97(4):627\u2013634","journal-title":"Thromb Haemost"},{"key":"3942_CR34","first-page":"183","volume":"29","author":"Wang","year":"2008","unstructured":"Wang W, Ji CY, Ye JJ et al (2008) Study of fibrinolysis inhibitors in 117 acute leukemia patients. Zhonghua Xue Ye Xue Za Zhi 29(3):183\u2013186","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"3942_CR35","first-page":"235","volume":"19","author":"Wada","year":"2002","unstructured":"Wada H NT, Watanabe R, Shiku H, Sakuragawa N (2002) Plasma levels of plasminogen activator inhibitor-1 (PAI-1) and thrombin activatable fibrinolysis inhibitor (TAF\u0130) in patients with disseminated intravascular coagulation (DIC). Turk J Haematologica 19:235\u2013237","journal-title":"Turk J Haematologica"},{"key":"3942_CR36","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1177\/1076029609350890","volume":"16","author":"Ermantas","year":"2010","unstructured":"Ermantas N, Guldiken S, Demir M, Tugrul A (2010) Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism. Clin Appl Thromb Hemost 16(5):568\u2013573","journal-title":"Clin Appl Thromb Hemost"},{"key":"3942_CR37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1161\/01.ATV.0000199246.08616.98","volume":"26","author":"Ceresa","year":"2006","unstructured":"Ceresa E, Brouwers E, Peeters M et al (2006) Development of ELISAs measuring the extent of TAFI activation. Arterioscler Thromb Vasc Biol 26(2):423\u2013428","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3942_CR38","first-page":"3","volume":"5","author":"Yazici","year":"2005","unstructured":"Yazici M, Aksakal E, Demircan S et al (2005) Is slow coronary flow related with inflammation and procoagulant state? Anadolu Kardiyol Derg 5(1):3\u20137","journal-title":"Anadolu Kardiyol Derg"},{"key":"3942_CR39","doi-asserted-by":"crossref","unstructured":"Li JJ, Qin XW, Li ZC et al (2007) Increased plasma C-reactive protein and interleukin-6 concentrations in patients with slow coronary flow. Clin Chim Acta 385(1\u20132):43\u201347","DOI":"10.1016\/j.cca.2007.05.024"},{"key":"3942_CR40","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.mehy.2006.09.070","volume":"69","author":"Li","year":"2007","unstructured":"Li JJ, Zheng X, Li J (2007) Statins may be beneficial for patients with slow coronary flow syndrome due to its anti-inflammatory property. Med Hypotheses 69:333\u2013337","journal-title":"Med Hypotheses"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-013-3942-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-013-3942-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-013-3942-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T21:42:03Z","timestamp":1646602923000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-013-3942-8"}},"subtitle":["Its role in slow coronary flow"],"short-title":[],"issued":{"date-parts":[[2013,9,27]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["3942"],"URL":"https:\/\/doi.org\/10.1007\/s00059-013-3942-8","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,27]]}}}